Most investors have tuned out the healthcare trade. Drug-pricing fights, political noise, and flat performance across biotech ETFs have pushed money toward flashier sectors. That fatigue has opened the door for something rare in today’s market — a profitable, dividend-paying company in the middle of a real turnaround that Wall Street hasn’t fully priced in.
This isn’t a moonshot startup or a one-drug story hanging on clinical trial luck. It’s a former industry giant that spent years out of favor after a past blockbuster created unrealistic expectations. Today its business looks nothing like it did a decade ago, and the numbers behind its shift tell a story most investors have not caught onto yet.
For those willing to look past sector pessimism, the setup resembles the early stages of a multi-year revaluation. The company has stable revenue, expanding margins, underappreciated growth catalysts in oncology and infectious disease, and one of the most reliable cash engines in biotech. Yet it trades at a discount to both peers and the broader market.
Why This Opportunity Exists
Biotech stocks have taken a beating over the past year. The Health Care Select Sector SPDR Fund is down, and major biotech ETFs like the SPDR S&P Biotech ETF and the iShares Biotechnology ETF have barely held above water. Some of that weakness is tied to politics. Uncertainty around drug approvals and coverage has made investors skittish.
Investor sentiment hasn’t helped. As debates over vaccine safety and government healthcare policy get louder, many have pulled back from the entire sector instead of separating durable businesses from speculative ones. Even profitable companies with years of clinical success have been thrown in the same bucket as risky pre-revenue players.
That disconnect has created pricing gaps — especially among companies whose past performance created a distorted narrative.
From One-Hit Label to Reinvention
Roughly a decade ago, this company shocked the industry with a breakthrough treatment that cured a major liver disease. The drug was so effective that it disrupted its own revenue stream — patients no longer needed long-term therapy. At the time, the stock surged above $120 a share before collapsing under the weight of expectations, pricing backlash, and declining treatment volume.
The market punished the company for being too successful. For nearly ten years, its share price drifted as investors assumed it had peaked. That assumption ignored a quiet transformation that fundamentally changed where the company makes its money.
Only about 10 percent of revenue now comes from liver treatments. Two-thirds comes from dominant HIV therapies with recurring demand and strong margins. The company also built a serious foothold in oncology, doubling that part of the business since 2020 through strategic acquisitions and new therapies.
That shift has strengthened its financial footing in ways investors have overlooked.
Gilead Sciences
The company is Gilead Sciences (NASDAQ: GILD). After years of being known for hepatitis C drugs like Sovaldi and Harvoni, the business is now powered by a diversified portfolio of HIV therapies, emerging oncology drugs, and next-generation treatments.
Public filings show that liver disease accounted for more than 90 percent of Gilead’s revenue a decade ago. As of 2024, that number is down to around 10 percent. Its HIV franchise is now the backbone of the company and considered best-in-class by multiple analysts. And oncology, once an afterthought, has become a fast-growing contributor with long-term potential.
Investors who stopped paying attention years ago are missing the new story.
Earnings Strength and a Low Bar
In its most recent quarter, Gilead beat expectations on both revenue and earnings. Management raised guidance for its HIV segment and signaled confidence in uptake for its next-generation therapy Yeztugo, which is still in its rollout phase.
Public analyst reports, such as coverage from Truist Securities available through mainstream financial outlets, have pointed to leading demand indicators for Yeztugo. Some state Medicaid programs have already signaled a willingness to cover the treatment — a positive sign for future accessibility and volume.
Consensus estimates call for earnings per share to jump more than 70 percent in 2025 and continue climbing in 2026. Gross margins are projected to rise above their five-year average, and the stock trades at roughly 13 times expected 2026 earnings — cheaper than many slower-growing healthcare names.
On top of that, Gilead pays a dividend that outpaces most biotech peers and many blue-chip companies outside the sector.
Oncology: The Hidden Upside
While HIV therapies drive consistency, oncology could drive rerating. Gilead’s antibody-drug conjugate Trodelvy has resumed growth with double-digit revenue gains. These types of therapies sit at the intersection of targeted treatment and biologics, a space gaining traction as traditional chemotherapy loses relevance.
Its CAR-T therapy programs — which use immune cells engineered to fight cancer — have been slower than expected. But upcoming candidates developed through partnerships are drawing optimism. Analysts covering the space publicly expect its multiple myeloma treatment Anito-cel to be among the most competitive when approved, possibly as soon as the next year.
That pipeline strength is often overlooked because investors still associate Gilead with its past, not its current trajectory.
Cleaner Balance Sheet, No Major Integrations Pending
Another advantage is operational focus. Gilead spent the past several years acquiring assets to diversify its lineup. Now it has no pending large deals, no major integrations distracting management, and no heavy cash drains tied to M&A.
That clarity strengthens earnings visibility and gives investors a cleaner read on performance.
The Policy Backdrop: A Risk and an Opportunity
Healthcare policy is always a source of concern, but Gilead is better positioned than most. It operates in areas with strong clinical outcomes and high medical necessity. That gives its drugs a better shot at reimbursement — even in difficult political climates.
Individual states may also play a bigger role going forward. As some Medicaid programs move to cover therapies like Yeztugo, the path to adoption becomes less dependent on federal direction. That kind of decentralized support can create momentum even when national policy wavers.
The Numbers Behind the Sentiment Gap
Here’s what stands out from publicly available financial sources:
- Forward earnings growth above 70 percent from 2024 to 2025
- Price-to-earnings multiple well below market averages
- Dividend yield higher than most large-cap biotechs
- Oncology revenue growing double digits in key segments
- HIV dominance with entrenched recurring revenue
Analysts’ average price target points to low double-digit upside from current levels — and that does not account for any major pipeline surprises or multiple expansion.
Investor Takeaways
For investors debating whether biotech is worth the headache, Gilead offers a different setup than the speculative names that dominate headlines. The company generates real cash, owns category-leading products, and has margin expansion ahead of it.
The market’s memory of its hepatitis C boom-and-drop has helped suppress its valuation. That is exactly why there is room for upside if sentiment catches up to fundamentals.
This is not a trade built on hype or a binary approval. It is a recovery story built on recurring revenue, a maturing oncology portfolio, and a cost structure that supports both dividends and research.
Why the Window May Not Stay Open
Turnarounds like this usually reprice in stages:
- Earnings catch up before sentiment
- Analyst upgrades trickle in
- Institutions rotate back in
- Retail rediscovers the story late
Gilead appears to be somewhere between stages one and two. Analysts at large institutions have started raising targets, but the broader investor base hasn’t returned.
That is often the sweet spot for entry — not when headlines are loud, but when the fundamentals have quietly turned.
What Could Accelerate the Rerating
Several near-term catalysts could push the stock higher:
- Stronger-than-expected HIV drug adoption
- Regulatory milestones in oncology
- EPS beats in 2025 and beyond
- Dividend increases funded by cash flow
- Broader rotation back into undervalued healthcare
As large-cap pharma and biotech names consolidate, companies with stable income and durable pipelines tend to outperform. Gilead now fits that profile more than it has in a decade.
The Bottom Line
This is a case where investor neglect created opportunity. A company once seen as a one-hit wonder has rebuilt itself around recurring revenue, diversified therapies, and forward momentum — but most of the market still views it through a 10-year-old lens.
Biotech sentiment may stay choppy, but individual winners will separate from the pack. Gilead Sciences has already done the hard part: restructuring its business, delivering profits, and laying out visible growth paths. What it has not yet done is reclaim investor attention in proportion to those changes.
That disconnect is where upside lives.
If Wall Street waits for the sector to recover before revaluing the leaders within it, the entry point disappears. Investors who get ahead of that shift don’t need perfect timing — only the ability to spot when a company has already turned the corner while everyone else is still looking backward.
Gilead spent a decade out of favor. That lost decade is over, but the stock still trades like it isn’t.
About Author
